Robin Casey
Alberta Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robin Casey.
Clinica Chimica Acta | 2010
Christiane Auray-Blais; Aimé Ntwari; Joe T.R. Clarke; David G. Warnock; João Paulo Oliveira; Sarah P. Young; David S. Millington; Daniel G. Bichet; Sandra Sirrs; Michael West; Robin Casey; Wuh-Liang Hwu; Joan Keutzer; X. Kate Zhang; René Gagnon
BACKGROUND Fabry disease is characterized by accumulation of glycosphingolipids, such as globotriaosylceramide (Gb(3)), in many tissues and body fluids. A novel plasma biomarker, globotriaosylsphingosine (lyso-Gb(3)), is increased in patients with the disease. Until now, lyso-Gb(3) was not detectable in urine, possibly because of the presence of interfering compounds. METHODS We undertook to: 1) characterize lyso-Gb(3) in urine; 2) develop a method to quantitate urinary lyso-Gb(3) by mass spectrometry; 3) evaluate urinary lyso-Gb(3) as a potential biomarker for Fabry disease; and 4) determine whether lyso-Gb(3) is an inhibitor of α-galactosidase A activity. We analyzed urinary lyso-Gb(3) from 83 Fabry patients and 77 healthy age-matched controls. RESULTS The intraday and interday bias and precision of the method were <15%. Increases in lyso-Gb(3)/creatinine correlated with the concentrations of Gb(3) (r(2)=0.43), type of mutations (p=0.0006), gender (p<0.0001) and enzyme replacement therapy status (p=0.0012). Urine from healthy controls contained no detectable lyso-Gb(3). Lyso-Gb(3) did not inhibit GLA activity in dried blood spots. Increased urinary excretion of lyso-Gb(3) of Fabry patients correlated well with a number of indicators of disease severity. CONCLUSION Lyso-Gb(3) is a reliable independent biomarker for clinically important characteristics of Fabry disease.
Neuromuscular Disorders | 2015
Laura E. Case; Carl Bjartmar; Claire Morgan; Robin Casey; Joel Charrow; John P. Clancy; Majed Dasouki; Stephanie DeArmey; Khan Nedd; Mary Nevins; Heidi Peters; Dawn Phillips; Zachary Spigelman; Cynthia J. Tifft; Priya S. Kishnani
Emerging phenotypes in long-term survivors with Pompe disease on standard enzyme replacement therapy (ERT) (alglucosidase alfa 20 mg/kg/2 weeks) can include patients with worsening motor function. Whether higher doses of ERT improve skeletal function in these patients has not been systematically studied. This exploratory, randomized, open-label, 52-week study examined the safety and efficacy of 2 ERT regimens of alglucosidase alfa (20 mg/kg/week or 40 mg/kg/2 weeks) in 13 patients with Pompe disease and clinical decline or a lack of improvement on standard ERT: late-onset (n = 4), infantile-onset (n = 9). Cross-reactive immunologic material assay-negative patients were excluded. Eleven of 13 patients completed the study. Trends for improvement were seen in total gross motor function, but not mobility; however, 6 (late-onset, 2; infantile-onset, 4) of 11 patients (55%) who met the entry criteria of motor decline (late-onset, 4; infantile-onset, 7) showed improvement in motor and/or mobility skills. No between-regimen differences in efficacy emerged. Two case studies highlight the benefits of increased ERT dose in patients with Pompe disease experiencing clinical decline. Both alternative regimens were generally well tolerated. This study was limited by the small sample size, which is not uncommon for small clinical studies of rare diseases. Additionally, the study did not include direct assessment of muscle pathology, which may have identified potential causes of decreased response to ERT. Results were inconclusive but suggest that increased ERT dose may be beneficial in some patients with Pompe disease experiencing motor decline. Controlled studies are needed to clarify the benefits and risks of this strategy.
Neuropathology | 2012
Harvey B. Sarnat; Laura Flores-Sarnat; Robin Casey; Patrick Scott; Aneal Khan
Electron microscopy (EM) is a reliable method for diagnosing mitochondrial diseases in striated muscle biopsy in infancy. Ultrastructural alterations in mitochondria of myofibers are well documented, but there are few studies of endothelial involvement in intramuscular capillaries. Quadriceps femoris biopsies of five representative infants and toddlers, ages neonate to 3.5 years, were performed because of clinical and laboratory data consistent with mitochondrial disease without mitochondrial DNA (mtDNA) mutations and likely with nuclear DNA mutations. Pathological studies included histochemistry, EM, respiratory chain enzymatic assay and mtDNA sequencing and deletion/duplication analysis. EM demonstrated frequent and severe alterations of mitochondria in capillary endothelium. The most constant changes included: either too few or fragmented cristae; stacked and whorled cristae; paracrystallin structures that often were large and spheroid with stress fractures; closely apposed membranes of granular endoplasmic reticulum surrounding mitochondria with loss of the normal intervening layer of cytoplasm; long narrow, thin looped microvilli extending into the lumen; and thick microvilli containing large, abnormal mitochondria. We conclude that mitochondrial cytopathies in early life exhibit more severe ultrastructural alterations in the endothelium than in myofibers and that paracrystallin body structure differs, perhaps due to less rigid surrounding structures. This distribution may explain the frequent lack of prominent histochemical and biochemical abnormalities in muscle biopsies of young patients. Endothelial changes do not distinguish the genetic defects. Vascular involvement in brain contributes to cerebral lesions and neuronal death by impairment of molecular and nutrient transport and ischemia; endothelium in muscle may reflect similar changes.
Canadian Journal of Neurological Sciences | 2014
Aneal Khan; Colleen Curtis; Harvey B. Sarnat; Alfredo Pinto-Rojas; Khemissa Bejaoui; Xing-Chang Wei; Robin Casey
Niemann Pick disease type C (NPC) is a neurodegenerative disorder that classically presents in children with hepatosplenomegaly, liver abnormalities (such as jaundice and coagulopathy) and developmental delay1,2. Niemann Pick type C is an autosomal recessive disease caused mostly commonly by mutations in the NPC1 gene and less frequently by mutations in the NPC2 gene3. The underlying pathophysiology of NPC involves abnormal trafficking of cholesterol from late endosomes / lysosomes after low density lipoprotein-mediated uptake4. The diagnosis is currently established by either gene sequencing or cultured skin fibroblast studies showing decreased cholesterol esterification and increased filipin staining5. We find this case to be important for the following reasons: 1. to provide knowledge of a novel variant present in the Stoney Nakoda Nation, 2. to show that NPC can be present in and obscured by an overlying Epstein-Barr Virus (EBV) infection and 3. that the finding of a non-specific mitochondrial cytopathy in a patient with seizures and chronic encephalopathy may be a secondary feature of underlying NPC. The Stoney Nakoda Nation originate from the larger Sioux nation, but migrated north and west to the North American prairie and Rocky mountains. Through interaction with other First Nations, and treaties with the Canadian government, they have come to reside in southern Alberta. There is no previous report of NPC in a Stoney Nakoda Nation child.
American Journal of Human Genetics | 2002
Deyanira Corzo; William T. Gibson; Kisha Johnson; Grant A. Mitchell; Guy LePage; Gerald F. Cox; Robin Casey; Carolyn Zeiss; Heidi Tyson; Garry R. Cutting; Gerald V. Raymond; Kirby D. Smith; Paul A. Watkins; Ann B. Moser; Hugo W. Moser; Steven J. Steinberg
The Journal of Pediatrics | 2009
Anke K. Bergmann; Inderneel Sahai; Jill F. Falcone; Judy Fleming; Adam Bagg; Caterina Borgna-Pignati; Robin Casey; Luca Fabris; Elizabeth O. Hexner; Lulu Mathews; Ribeiro Ml; Klaas J. Wierenga; Ellis J. Neufeld
Molecular Genetics and Metabolism | 2007
M.E. McCready; N.L. Carson; Pranesh Chakraborty; Joe T.R. Clarke; J.W. Callahan; M.A. Skomorowski; Alicia K. Chan; F. Bamforth; Robin Casey; C.A. Rupar; Michael T. Geraghty
Molecular Genetics and Metabolism | 2013
Christiane Auray-Blais; Michel Boutin; Pamela Lavoie; Robin Casey; Joe T.R. Clarke; Stephen Ronan Foley; Armand Keating; Aneal Khan; Michael West; Jeffrey A. Medin
Clinical Biochemistry | 2014
Maria Karaceper; Marni Brownell; Robin Casey; Pranesh Chakraborty; Doug Coyle; Linda Dodds; Annette Feigenbaum; Deshayne B. Fell; Scott D. Grosse; Astrid Guttmann; Anne-Marie Laberge; Aziz Mhanni; Fiona A. Miller; Meranda Nakhla; Cheryl Rockman-Greenberg; Rebecca Sparkes; Hilary Vallance; Brenda Wilson; Kumanan Wilson; Beth K. Potter
Molecular Genetics and Metabolism | 2007
Colleen McNeil; Robin Casey; Patrick Ferreira